40
American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis Dr. Amit Agrawal

Lupus nephritis 2012

Embed Size (px)

DESCRIPTION

Lupus nephritis Dr Amit Agrawal Pediatric Nephrologist

Citation preview

Page 1: Lupus nephritis 2012

American College of Rheumatology Guidelines for

Screening, Treatment, and Management of Lupus Nephritis

Dr. Amit Agrawal

Page 2: Lupus nephritis 2012

Disease Burden

• 35% of adults with SLE have clinical evidence of nephritis at the time of diagnosis.

• 50–60% developing nephritis during the first 10 years of disease.

• Higher in men than in women.• Survival with SLE - 95% at 5 years • 92% at 10 years • Lupus nephritis reduces survival 88% at 10 years

Page 3: Lupus nephritis 2012

Case definition

• Persistent proteinuria 0.5 gm per day• Or greater than 3+ by dipstickAnd/or• Cellular casts including red blood cells,

hemoglobin, granular, tubular, or mixed

Page 4: Lupus nephritis 2012

• Spot urine protein/creatinine ratio of >0.5Active Urinary Sediment:• >5 RBCs/hpf• >5WBCs/hpf in the absence of infection• cellular casts limited to RBC or WBC casts

Page 5: Lupus nephritis 2012

Renal Biopsy

• All patients with clinical evidence of active LN, previously untreated, undergo renal biopsy (unless strongly contraindicated) so that glomerular disease can be classified by current ISN/RPS classification

• Evaluated for activity and chronicity and for tubular and vascular changes

Page 6: Lupus nephritis 2012
Page 7: Lupus nephritis 2012
Page 8: Lupus nephritis 2012

Principles of treatment

• Class I and Class II- do not require immunosuppressive treatment.

• Class III And Class IV aggressive therapy with glucocorticoids and immunosuppressive agents

• Class V when combined with class III or IV should be treated in the same manner as class III or IV

• Class VI requires preparation for renal replacement therapy rather than immunosuppression

Page 9: Lupus nephritis 2012

• All SLE patients with nephritis be treated with a background HCQ unless there is a contraindication

Rationale:• Lower rates of Flare• Reduced renal damage• Less clotting events

Page 10: Lupus nephritis 2012

• LN patients with proteinuria >0.5 gm per 24 hours should have blockade of the renin–angiotensin system, which drives intraglomerular pressure

Rationale:• Reduces proteinuria by 30%, and • Significantly delays doubling of serum

creatinine • Delays progression to end-stage renal disease

Page 11: Lupus nephritis 2012

• Control of hypertension, with a target of <130/80 mm Hg

• Statin therapy be introduced in patients with low-density lipoprotein cholesterol >100 mg/dl

Page 12: Lupus nephritis 2012
Page 13: Lupus nephritis 2012

Class V Management

Page 14: Lupus nephritis 2012
Page 15: Lupus nephritis 2012
Page 16: Lupus nephritis 2012

Class I LN (minimal-mesangial LN)

• Treatment as dictated by the extrarenal clinical manifestations of lupus

RATIONALE:• Class I LN has no clinical kidney

manifestations.• Class I LN is not associated with long-term

impairment of kidney function

Page 17: Lupus nephritis 2012

Class II LN (mesangial-proliferative LN)

• Treat patients with class II LN and proteinuria <1 g/d as dictated by the extrarenal clinical manifestations of lupus. • Class II LN with proteinuria >3 g/d be treated

with corticosteroids or CNIs as described for MCD.

RATIONALE: There are no evidence-based data on the

treatment of class II LN.

Page 18: Lupus nephritis 2012

Class III LN (focal LN) and class IV LN (diffuse LN)

• Initial therapy with corticosteroids , combined with either cyclophosphamide or MMF

• if patients have worsening LN (rising SCr, worsening proteinuria) during the first 3 months of treatment, a change be made to an alternative recommended initial therapy, or a repeat kidney biopsy be performed to guide further treatment

Page 19: Lupus nephritis 2012

Regimens for initial therapy in class III/class IV LN

Page 20: Lupus nephritis 2012
Page 21: Lupus nephritis 2012

Other Initial Regimens

• Azathioprine• Cyclosporine• Combination of tacrolimus and MMF

(sometimes called ‘‘multitarget’’ therapy).

Page 22: Lupus nephritis 2012

Important considerations

• Lifetime maximum of 36 g cyclophosphamide in patients with systemic lupus.

• The dose of cyclophosphamide should be decreased by 20%(CrCl 25–50 ml/min) or 30% (10–25 ml/min)

Page 23: Lupus nephritis 2012

Choice of Initial Therapy

• In severe class III/IV LN, a cyclophosphamide-containing protocol for initial therapy may be preferred.

• In patients with less severe proliferative LN, an initial regimen not containing cyclophosphamide should be considered.

Page 24: Lupus nephritis 2012

Class III LN and class IV LNmaintenance therapy

• Patients with class III and IV LN receive maintenance therapy with

• Azathioprine (1.5–2.5 mg/kg/d) or • MMF (1–2 g/d in divided doses), and • low-dose oral corticosteroids

Page 25: Lupus nephritis 2012

• CNIs with low-dose cortico-steroids be used for maintenance therapy in patients who are intolerant of MMF and azathioprine.

• After complete remission is achieved, maintenance therapy be continued for at least 1 year before consideration is given to tapering the immunosuppression.

Page 26: Lupus nephritis 2012

• If complete remission has not been achieved after 12 months of maintenance therapy, consider performing a repeat kidney biopsy before determining if a change in therapy is indicated.

• While maintenance therapy is being tapered, if kidney function deteriorates and/or proteinuria worsens, treatment be increased to the previous level of immunosuppression that controlled the LN.

Page 27: Lupus nephritis 2012

Duration of Therapy

• There is no evidence to help determine the duration of maintenance therapy.

• The average duration of immunosuppression was 3.5 years in seven RCTs.

• Immunosuppressive therapy should usually be slowly tapered after patients have been in complete remission for a year.

Page 28: Lupus nephritis 2012

• Immunosuppression should be continued for patients who achieve only a partial remission.

• The strategy of trying to convert a partial remission to a complete remission by increasing corticosteroids or using alternative immunosuppressive agents is not supported by evidence.

Page 29: Lupus nephritis 2012

Predictors of Response to Treatment of Class III/IV LN

Predictors for not achieving remission:• SCr at the start of treatment• Magnitude of increase in SCr during relapse• Delay in starting therapy for more than 3

months after a clinical diagnosis of LN.• Severity of proteinuria• Failure to achieve complete remission a major

risk factor for kidney relapse.

Page 30: Lupus nephritis 2012

Monitoring Therapy of Class III/IV LN

• Proteinuria • SCr• Urine sediment• C3 and C4,• Anti–double-stranded DNA antibodies

Page 31: Lupus nephritis 2012

Class V LN (membranous LN)

• Patients with class V LN,normal kidney function, and non–nephrotic-range proteinuria be treated with antiproteinuric and antihypertensive medications, and only receive corticosteroids and immunosup-pressives as dictated by the extrarenal man-ifestations of systemic lupus.

Page 32: Lupus nephritis 2012

• Pure class V LN and persistent nephrotic proteinuria be treated with corticosteroids plus an additional immunosuppressive agent:

• cyclophosphamide • CNI • MMF • Azathioprine

Page 33: Lupus nephritis 2012

General treatment of LN

• All patients with LN of any class are treated with hydroxychloroquine(maximum daily dose of 6–6.5 mg/kg ideal body weight), unless they have a specific contraindication to this drug.

Page 34: Lupus nephritis 2012

Class VI LN (advanced sclerosis LN)

• Treated with corticosteroids and immuno-suppressives only as dictated by the extrarenal manifestations of systemic lupus.

Page 35: Lupus nephritis 2012

Relapse of LN

• Relapse of LN after complete or partial remission be treated with the initial therapy followed by the maintenance therapy that was effective in inducing the original remission

• If resuming the original therapy would put the patient at risk for excessive lifetime cyclophosphamide exposure, then we suggest a non cyclophosphamide based initial regimen be used.

Page 36: Lupus nephritis 2012

• Consider a repeat kidney biopsy during relapse if there is suspicion that the histologic class of LN has changed, or there is uncertainty whether a rising SCr and/or worsening proteinuria represents disease activity or chronicity.

Page 37: Lupus nephritis 2012
Page 38: Lupus nephritis 2012

Treatment of resistant disease

• In patients with worsening SCr and/or protei-nuria after completing one of the initial treatment regimens, consider performing a repeat kidney biopsy to distinguish active LN from scarring.

• Treat patients with worsening SCr and/or proteinuria who continue to have active LN on biopsy with one of the alternative initial treat-ment regimens.

Page 39: Lupus nephritis 2012

• Nonresponders who have failed more than one of the recommended initial regimens may be considered for treatment with rituximab, i.v.immunoglobulin, or CNIs.

Page 40: Lupus nephritis 2012

Systemic lupus and thrombotic microangiopathy

• The antiphospholipid anti-body syndrome (APS) involving the kidney in systemic lupus patients, with or without LN,be treated by anticoagulation target INR 2–3.

• Patients with systemic lupus and thrombotic thrombocytopenic purpura (TTP) receive plasma exchange as for patients with TTP without systemic lupus.